PE20081225A1 - Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico - Google Patents
Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoicoInfo
- Publication number
- PE20081225A1 PE20081225A1 PE2007001290A PE2007001290A PE20081225A1 PE 20081225 A1 PE20081225 A1 PE 20081225A1 PE 2007001290 A PE2007001290 A PE 2007001290A PE 2007001290 A PE2007001290 A PE 2007001290A PE 20081225 A1 PE20081225 A1 PE 20081225A1
- Authority
- PE
- Peru
- Prior art keywords
- crystalline forms
- oxadiazol
- fluorophenyl
- benzoic acid
- refers
- Prior art date
Links
- -1 2-FLUOROPHENYL Chemical class 0.000 title abstract 2
- 239000005711 Benzoic acid Substances 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002028 premature Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84732606P | 2006-09-25 | 2006-09-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081225A1 true PE20081225A1 (es) | 2008-09-04 |
Family
ID=39123850
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001746A PE20120768A1 (es) | 2006-09-25 | 2007-09-25 | Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4\oxadiazol-3-il]-benzoico |
| PE2015001242A PE20151445A1 (es) | 2006-09-25 | 2007-09-25 | Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico |
| PE2007001290A PE20081225A1 (es) | 2006-09-25 | 2007-09-25 | Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011001746A PE20120768A1 (es) | 2006-09-25 | 2007-09-25 | Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4\oxadiazol-3-il]-benzoico |
| PE2015001242A PE20151445A1 (es) | 2006-09-25 | 2007-09-25 | Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico |
Country Status (29)
| Country | Link |
|---|---|
| US (10) | US7863456B2 (enExample) |
| EP (2) | EP2559689B1 (enExample) |
| JP (6) | JP5714228B2 (enExample) |
| KR (1) | KR101430144B1 (enExample) |
| CN (3) | CN102382075B (enExample) |
| AR (2) | AR062963A1 (enExample) |
| AU (1) | AU2007300542B2 (enExample) |
| BR (1) | BRPI0717107A2 (enExample) |
| CA (1) | CA2663574C (enExample) |
| CL (1) | CL2007002743A1 (enExample) |
| DK (1) | DK2076501T3 (enExample) |
| ES (2) | ES2563958T3 (enExample) |
| HK (1) | HK1207070A1 (enExample) |
| HU (1) | HUE028503T2 (enExample) |
| IL (1) | IL197717A (enExample) |
| LT (1) | LTC2076501I2 (enExample) |
| MX (2) | MX2009003160A (enExample) |
| MY (1) | MY191209A (enExample) |
| NO (1) | NO341858B1 (enExample) |
| NZ (1) | NZ575795A (enExample) |
| PE (3) | PE20120768A1 (enExample) |
| PL (2) | PL2076501T3 (enExample) |
| PT (1) | PT2076501E (enExample) |
| SG (2) | SG185979A1 (enExample) |
| SI (1) | SI2076501T1 (enExample) |
| TW (2) | TWI452038B (enExample) |
| UA (1) | UA99600C2 (enExample) |
| WO (1) | WO2008039431A2 (enExample) |
| ZA (1) | ZA200901949B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3889142B1 (en) | 2003-04-11 | 2022-06-15 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| CA2603402C (en) * | 2005-04-08 | 2017-10-31 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| IN2014CN04406A (enExample) | 2006-03-30 | 2015-09-04 | Ptc Therapeutics Inc | |
| SG185979A1 (en) * | 2006-09-25 | 2012-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| DK2073805T3 (da) | 2006-10-12 | 2015-06-15 | Ptc Therapeutics Inc | Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation |
| PL2544679T3 (pl) | 2010-03-12 | 2019-10-31 | Omeros Corp | Inhibitory PDE10 oraz powiązane kompozycje i sposoby |
| WO2014153643A1 (en) * | 2013-03-26 | 2014-10-02 | The University Of British Columbia | Compositions and methods for use thereof in the treatment of aniridia |
| EP2981597A1 (en) | 2013-04-03 | 2016-02-10 | GFO Oil LLC | Methods and systems for generating aldehydes from organic seed oils |
| HUE048874T2 (hu) | 2013-09-06 | 2020-08-28 | Aurigene Discovery Tech Ltd | 1,2,4-oxadiazol-származékok, mint immunmodulátorok |
| CN106455571A (zh) | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
| NZ716462A (en) | 2014-04-28 | 2017-11-24 | Omeros Corp | Optically active pde10 inhibitor |
| NZ716494A (en) | 2014-04-28 | 2017-07-28 | Omeros Corp | Processes and intermediates for the preparation of a pde10 inhibitor |
| KR101703137B1 (ko) | 2014-05-30 | 2017-02-07 | 선문대학교 산학협력단 | 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| CN105461650B (zh) * | 2014-09-12 | 2018-04-13 | 杭州普晒医药科技有限公司 | 一种噁二唑化合物的溶剂化物及其制备方法 |
| AU2016230793B2 (en) | 2015-03-10 | 2021-03-25 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| CA2980801A1 (en) | 2015-04-24 | 2016-10-27 | Omeros Corporation | Pde10 inhibitors and related compositions and methods |
| TW201729807A (zh) | 2015-10-30 | 2017-09-01 | Ｐｔｃ治療公司 | 用於治療癲癇的方法 |
| US9920045B2 (en) | 2015-11-04 | 2018-03-20 | Omeros Corporation | Solid state forms of a PDE10 inhibitor |
| EP3442512A4 (en) * | 2016-04-15 | 2020-07-22 | The UAB Research Foundation | METHODS AND COMPOUNDS FOR STIMULATING THE TRANSLECTURE OF PREMATURE TERMINATION CODONS |
| WO2018050706A1 (en) * | 2016-09-13 | 2018-03-22 | Marco Cipolli | Method of treatment of shwachman-diamond syndrome |
| WO2019061324A1 (en) | 2017-09-29 | 2019-04-04 | Curis Inc. | CRYSTALLINE FORMS OF IMMUNOMODULATORS |
| EP3694841A1 (en) | 2017-10-11 | 2020-08-19 | Aurigene Discovery Technologies Limited | Crystalline forms of 3-substituted 1,2,4-oxadiazole |
| MX2020004531A (es) | 2017-11-03 | 2020-08-03 | Aurigene Discovery Tech Ltd | Inhibidores dobles de tim-3 y las vias de pd-1. |
| EP3706798A1 (en) | 2017-11-06 | 2020-09-16 | Aurigene Discovery Technologies Limited | Conjoint therapies for immunomodulation |
| EA202192767A1 (ru) | 2019-04-10 | 2021-12-29 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов |
| JP7339900B2 (ja) * | 2020-02-26 | 2023-09-06 | 新 井上 | 視野異常診断方法、視野異常診断装置 |
| KR102665711B1 (ko) * | 2021-12-21 | 2024-05-14 | 재단법인 아산사회복지재단 | Ras 활성도를 이용한 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 Ras 활성 억제제를 포함하는 신경섬유종증 예방 또는 치료용 약학적 조성물 |
| WO2025110781A1 (ko) * | 2023-11-24 | 2025-05-30 | 재단법인 아산사회복지재단 | Ampd3를 포함하는 신경섬유종증 치료제에 대한 감수성 예측용 바이오마커 조성물 및 ampd3 저해제를 포함하는 신경섬유종증 예방 또는 치료용 약학 조성물 |
| CN118178408A (zh) * | 2024-03-22 | 2024-06-14 | 核工业总医院 | Ptc124在制备治疗血小板无力症的药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW264475B (enExample) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| RU2003138074A (ru) * | 2001-06-08 | 2005-02-20 | Цитови Инк. (US) | Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение |
| MY151199A (en) * | 2001-11-02 | 2014-04-30 | Rigel Pharmaceuticals Inc | Substituted diphenyl heterocycles useful for treating hcv infection |
| WO2004001010A2 (en) * | 2002-06-21 | 2003-12-31 | Ptc Therapeutics, Inc. | METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY |
| US6889231B1 (en) * | 2002-08-01 | 2005-05-03 | Oracle International Corporation | Asynchronous information sharing system |
| NZ538339A (en) * | 2002-08-09 | 2007-01-26 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| GB0303503D0 (en) * | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP3889142B1 (en) | 2003-04-11 | 2022-06-15 | PTC Therapeutics, Inc. | 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease |
| US20050075375A1 (en) * | 2003-05-14 | 2005-04-07 | Anadys Pharmaceuticals, Inc. | Heterocyclic compounds for treating hepatitis C virus |
| KR20070067165A (ko) * | 2004-10-13 | 2007-06-27 | 피티씨 테라퓨틱스, 인크. | 넌센스 변이 억제용 화합물, 및 이의 사용 방법 |
| EP1819340A2 (en) * | 2004-12-08 | 2007-08-22 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| CA2603402C (en) * | 2005-04-08 | 2017-10-31 | Ptc Therapeutics, Inc. | Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| MX2009002439A (es) | 2006-09-08 | 2009-03-27 | Ptc Therapeutics Inc | Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos. |
| SG185979A1 (en) * | 2006-09-25 | 2012-12-28 | Ptc Therapeutics Inc | Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| CN106455571A (zh) * | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
-
2007
- 2007-09-24 SG SG2012082715A patent/SG185979A1/en unknown
- 2007-09-24 CN CN201110283329.XA patent/CN102382075B/zh active Active
- 2007-09-24 DK DK07838770.1T patent/DK2076501T3/da active
- 2007-09-24 MY MYPI20091186A patent/MY191209A/en unknown
- 2007-09-24 AR ARP070104212A patent/AR062963A1/es not_active Application Discontinuation
- 2007-09-24 ES ES07838770.1T patent/ES2563958T3/es active Active
- 2007-09-24 CA CA2663574A patent/CA2663574C/en active Active
- 2007-09-24 CN CN201410561812.3A patent/CN104341371A/zh active Pending
- 2007-09-24 KR KR1020097008202A patent/KR101430144B1/ko active Active
- 2007-09-24 ZA ZA200901949A patent/ZA200901949B/xx unknown
- 2007-09-24 CN CNA200780043582XA patent/CN101541770A/zh active Pending
- 2007-09-24 EP EP12185448.3A patent/EP2559689B1/en active Active
- 2007-09-24 AU AU2007300542A patent/AU2007300542B2/en active Active
- 2007-09-24 CL CL200702743A patent/CL2007002743A1/es unknown
- 2007-09-24 UA UAA200904012A patent/UA99600C2/ru unknown
- 2007-09-24 SG SG10201609581TA patent/SG10201609581TA/en unknown
- 2007-09-24 ES ES12185448.3T patent/ES2655338T3/es active Active
- 2007-09-24 HU HUE07838770A patent/HUE028503T2/en unknown
- 2007-09-24 NZ NZ575795A patent/NZ575795A/en unknown
- 2007-09-24 SI SI200731750A patent/SI2076501T1/sl unknown
- 2007-09-24 PT PT78387701T patent/PT2076501E/pt unknown
- 2007-09-24 JP JP2009529270A patent/JP5714228B2/ja active Active
- 2007-09-24 BR BRPI0717107-2A patent/BRPI0717107A2/pt not_active Application Discontinuation
- 2007-09-24 PL PL07838770T patent/PL2076501T3/pl unknown
- 2007-09-24 MX MX2009003160A patent/MX2009003160A/es active IP Right Grant
- 2007-09-24 MX MX2011007120A patent/MX344418B/es unknown
- 2007-09-24 EP EP07838770.1A patent/EP2076501B8/en active Active
- 2007-09-24 WO PCT/US2007/020633 patent/WO2008039431A2/en not_active Ceased
- 2007-09-24 US US11/904,005 patent/US7863456B2/en active Active
- 2007-09-24 PL PL12185448T patent/PL2559689T3/pl unknown
- 2007-09-25 PE PE2011001746A patent/PE20120768A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2015001242A patent/PE20151445A1/es not_active Application Discontinuation
- 2007-09-25 PE PE2007001290A patent/PE20081225A1/es not_active Application Discontinuation
- 2007-09-26 TW TW096135785A patent/TWI452038B/zh active
- 2007-09-26 TW TW103104823A patent/TWI496775B/zh active
-
2009
- 2009-03-19 IL IL197717A patent/IL197717A/en active IP Right Grant
- 2009-04-16 NO NO20091488A patent/NO341858B1/no unknown
-
2010
- 2010-10-27 US US12/913,213 patent/US8394966B2/en active Active
-
2013
- 2013-02-12 US US13/764,807 patent/US8748625B2/en active Active
-
2014
- 2014-04-25 US US14/261,774 patent/US9309206B2/en active Active
-
2015
- 2015-01-09 JP JP2015003265A patent/JP6407733B2/ja active Active
- 2015-08-10 HK HK15107681.2A patent/HK1207070A1/xx unknown
-
2016
- 2016-03-14 US US15/068,792 patent/US10028939B2/en active Active
- 2016-04-22 LT LTPA2016012C patent/LTC2076501I2/lt unknown
-
2017
- 2017-05-29 JP JP2017106030A patent/JP6495375B2/ja active Active
- 2017-08-07 AR ARP170102217A patent/AR109300A2/es unknown
-
2018
- 2018-06-22 US US16/015,389 patent/US10300047B2/en active Active
-
2019
- 2019-03-06 JP JP2019040137A patent/JP2019104752A/ja not_active Withdrawn
- 2019-04-10 US US16/380,218 patent/US10959988B2/en not_active Expired - Fee Related
-
2020
- 2020-07-07 US US16/921,934 patent/US20200330440A1/en not_active Abandoned
-
2021
- 2021-02-24 US US17/183,342 patent/US20210330647A1/en not_active Abandoned
- 2021-05-31 JP JP2021090763A patent/JP7245868B2/ja active Active
- 2021-09-30 US US17/490,725 patent/US20220023268A1/en not_active Abandoned
-
2023
- 2023-03-13 JP JP2023038770A patent/JP2023078271A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081225A1 (es) | Formas cristalinas del acido 3-[5-(2-fluorofenil)-[1,2,4]oxadiazol-3-il]-benzoico | |
| EA201200794A1 (ru) | Триазолопиридины | |
| MX2011012122A (es) | Derivados de tiofeno. | |
| WO2008079291A3 (en) | Substituted heterocycles and methods of use | |
| EA201270215A1 (ru) | Apaf-1 ингибиторные соединения | |
| DOP2011000218A (es) | Derivados de sulfonamida | |
| DOP2011000279A (es) | Derivados de benzofuranilo usados como inhibidores de glucoquinasa | |
| MX2009006543A (es) | Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer. | |
| GT200800242A (es) | Derivados biciclicos como inhibidores de cetp | |
| UA98373C2 (ru) | Конденсированные гетероциклические производные и их применение как c-met ингибиторов | |
| EA201490774A1 (ru) | Новые производные оксазина и их применение при лечении заболевания | |
| EA201490491A1 (ru) | Производные 2-амино-4-(пиридин-2-ил)-5,6-дигидро-4h-1,3-оксазинов и их использование в качестве ингибиторов bace-1 и/или bace-2 | |
| NI200800294A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen. | |
| EA200971115A1 (ru) | Новые ингибиторы обратной транскриптазы вич | |
| EA201270410A1 (ru) | Производное инденона и содержащая его фармацевтическая композиция | |
| GT200600086A (es) | Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
| GEP20135806B (en) | Lactams as beta secretase inhibitors | |
| ATE465719T1 (de) | Oral zerfallende zusammensetzung von olanzapin oder donepezil | |
| AR058098A1 (es) | Derivados de acidos dicarboxilicos y su uso | |
| ATE372995T1 (de) | Benzo(b)(1,4)dioxepinderivate | |
| UY29648A1 (es) | Derivados de piridopirimidina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| NZ597866A (en) | Therapeutic lactams | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| CY1108588T1 (el) | ΑΝΑΣΤΟΛΕΙΣ ΟΥΔΕΤΕΡΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (ΝΕΡ) ΚΑΙ ΑΝΘΡΩΠΙΝΗΣ ΔΙΑΛΥΤΗΣ ΕΝΔΟΠΕΠΤΙΔΑΣΗΣ (hSEP) ΓΙΑ ΤΗΝ ΠΡΟΦΥΛΑΞΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΝΕΥΡΟΕΚΦΥΛΙΣΤΙΚΩΝ ΠΑΘΗΣΕΩΝ | |
| TW200800993A (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |